IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
Authors:
Open Access
- 29 August 2024
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (14) , 2077-2087
Abstract
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and adolescents and in recent decades, the survival rates have risen to >90% in children largely due the introduction of risk adapted therapy. Therefore, knowledge of factors influencing risk of relapse is important. The transcription factor IKAROS is a regulator of lymphocyte development and alterations of its coding gene, IKZF1, are frequent in ALL and are associated with higher relapse risk. This concise review will discuss the normal function of IKAROS together with the effect of gene alterations in ALL such as relieved energy restriction and altered response to anti-leukemic drugs. Besides the biology, the clinical impact of gene alterations in the different subtypes of ALL will be discussed. Finally, possibilities for treating ALL with IKZF1 alterations will be considered including novel therapies like cell signaling inhibitors and immunotherapy.Keywords
Funding Information
- Princess Maxima Center Foundation Talent Programme
This publication has 118 references indexed in Scilit:
- Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemiaAnnals of Hematology, 2023
- Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemiaClinical and Translational Medicine, 2023
- The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trialPediatric Blood & Cancer, 2023
- Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocolHematological Oncology, 2022
- Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemiaFrontiers of Medicine, 2021
- Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemiaGenes, Chromosomes and Cancer, 2019
- Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocolsCancer, 2015
- Cooperative genetic changes in pediatric B‐cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1Genes, Chromosomes and Cancer, 2015
- Zinc finger‐mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development.The EMBO Journal, 1996
- The ikaros gene is required for the development of all lymphoid lineagesCell, 1994